Pfizer seeks FDA approval to prescribe Celebrex to toddlers as young as 2

Email this article to a friend

Printable Version

Articles Related to This Article: • Pfizer pleads guilty to felony crime in fraudulent marketing of Bextra, pays billions in fines • Viagra Now Being Increasingly Used as a Recreational Drug By Younger Men: Is Pfizer Responsible? • Lipitor class action lawsuits expand; Pfizer cover-up alleged Support NaturalNews advertisers - Advertise with NaturalNews Help support NaturalNews with health books and educational programs from Truth Publishing: • Swine Flu Advanced Preparedness • 8 Weeks to Vibrant Health • Raw In Ten Minutes (recipes) • How to Halt Diabetes in 25 Days ... and much more.

(NaturalNews) Drug giant Pfizer Inc. is set to meet this Wednesday with a panel of advisors from the Food and Drug Administration to review the company's request to expand the use of its painkiller Celebrex -- which has been linked to serious heart risks -- in children as young as 2.

Celebrex -- the first FDA-approved Cox-2 inhibitor on the market -- was shown in recent tests to double or even triple the risk of heart attack, stroke and death. The anti-inflammatory drug is the last Cox-2 inhibitor left on the market after Merck & Co. pulled Vioxx in late 2004, following news that it doubled the risk of heart attack and stroke in patients.

A 2004 study funded by the National Cancer Institute to test the effects of Celebrex in preventing colon cancer was halted early after patients experienced high rates of heart attack, heart death and stroke.

Patients taking a daily 400 mg dose of the drug had 2.5 times as many heart attacks, strokes and deaths as control patients, while those taking 800 mg of the drug per day had 3.4 times the cardiovascular events as the control group.

Though experts are calling for Celebrex to be pulled from the market, Wednesday's meeting between Pfizer and the FDA will determine if the drug's benefits outweigh its risks in children as young as 2 who have arthritis.

Consumer health advocate Mike Adams, author of "Grocery Warning," said it was "outrageous" that the FDA would consider approving idea of treating toddlers with dangerous arthritis drugs.

"Drugging our babies with toxic painkillers that greatly increase the risk of heart attacks and strokes is not the way to raise a generation of healthy children," Adams said. "If there was anything resembling sanity remaining at the FDA, they would look at this idea in astonishment and reject it outright."

FDA adviser Arthur Levin, who was invited to attend Wednesday's meeting, said previously that all sales of Celebrex should be halted.

Pfizer is also under fire from critics who say the company heavily promoted the painkiller through direct-to-consumer advertising before all its risks were known.

###

Get articles like this delivered to you FREE in our popular email newsletter

Related CounterThink Cartoons:

Related Articles: • Pfizer pleads guilty to felony crime in fraudulent marketing of Bextra, pays billions in fines • Viagra Now Being Increasingly Used as a Recreational Drug By Younger Men: Is Pfizer Responsible? • Lipitor class action lawsuits expand; Pfizer cover-up alleged	Take Action: Support NaturalNews.com Email this article to a friend Share this article on: NewsVine | digg | del.icio.us Permalink to this article: http://www.NaturalNews.com/021226_Pfizer_Celebrex_toddlers.html Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link. Embed article link: (copy HTML code below): <a href = "http://www.NaturalNews.com/021226_Pfizer_Celebrex_toddlers.html">Pfizer seeks FDA approval to prescribe Celebrex to toddlers as young as 2</a>